Fosun Pharma (02196.HK) responds to the acquisition of Green Valley Pharmaceuticals: Mannitol sodium capsules confirmed clinical research has been recognized by the drug regulatory center, with a cumulative enrollment of 580 cases.

According to the WiseFinance app, on the evening of December 22, Fosun Pharma (600196.SH,02196) issued an announcement regarding the reply to the Shanghai Stock Exchange's regulatory work letter on the investment in Lvgu Pharmaceutical, disclosing details about its specific transaction method, clinical progress, and subsequent integration.